Stifel Nicolaus Initiates Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)

Stock analysts at Stifel Nicolaus initiated coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report released on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $43.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 39.66% from the stock’s previous close.

Several other research firms have also recently commented on KRSA. UBS Group initiated coverage on shares of Cyclerion Therapeutics in a research report on Friday. They issued a “buy” rating and a $55.00 target price for the company. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $49.00.

Cyclerion Therapeutics Stock Down 3.5%

Shares of KRSA stock traded down $1.12 during trading hours on Monday, reaching $30.79. The stock had a trading volume of 4,422 shares, compared to its average volume of 313,500. The stock has a market cap of $20.63 million, a PE ratio of -2.65 and a beta of 1.75. Cyclerion Therapeutics has a twelve month low of $7.19 and a twelve month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.